Download or read book Engineering Non antibody Scaffolds and Growth Factor Ligands as Protein Therapeutics and Diagnostics written by Cheuk Lun Leung and published by . This book was released on 2015 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Protein therapeutics have emerged as an important class of pharmaceuticals, with monoclonal antibodies making up the largest group of protein drugs. While antibodies have many desirable characteristics, there are some applications in which they may be the best option. In this dissertation, we describe alternative classes of proteins that can complement the use of antibodies in the development of protein therapeutics and diagnostics. Cystine knots, or knottins, have highly desirable properties for use as molecular imaging agents due to their small size and stable structure. Previous approaches to engineering knottins have focused on a small subset of knottin scaffolds; in this work we extend those studies to engineering Agatoxin, a knottin from spider venom, for high affinity binding to tumor associated integrins. Growth factor ligand-receptor interactions modulate many cell signaling pathways and biological processes. The vascular endothelial growth factor (VEGF) and the platelet-derived growth factor (PDGF) mediate two important signaling pathways involved in angiogenesis. In this work, we used the structural similarity of PDGF and VEGF to rationally design a chimeric PDGF/VEGF ligand, creating a multi-specific antagonist of their receptors PDGFR and VEGFR. The PDGF/VEGF chimera was then engineered using combinatorial methods, including yeast surface display, for increased binding affinity to PDGFR and VEGFR. The resulting engineered protein variant strongly inhibited PDGFR and VEGFR signaling with in vitro cell models. Given the important roles of PDGFR and VEGFR in angiogenesis, the PDGF/VEGF chimera has potential application in anti-angiogenesis therapy. Collectively, the engineered proteins in this work demonstrate the promise of using non-antibody scaffolds and growth factor ligands for the development of protein therapeutics and diagnostics.

Download or read book Fusion Protein Technologies for Biopharmaceuticals written by Stefan R. Schmidt and published by John Wiley & Sons. This book was released on 2013-01-28 with total page 995 pages. Available in PDF, EPUB and Kindle. Book excerpt: The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

Download or read book Therapeutic Antibody Engineering written by William R Strohl and published by Elsevier. This book was released on 2012-10-16 with total page 697 pages. Available in PDF, EPUB and Kindle. Book excerpt: The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity

Download or read book Phage Display written by Carlos F. Barbas and published by CSHL Press. This book was released on 2001 with total page 724 pages. Available in PDF, EPUB and Kindle. Book excerpt: Phage-display technology has begun to make critical contributions to the study of molecular recognition. DNA sequences are cloned into phage, which then present on their surface the proteins encoded by the DNA. Individual phage are rescued through interaction of the displayed protein with a ligand, and the specific phage is amplified by infection of bacteria. Phage-display technology is powerful but challenging and the aim of this manual is to provide comprehensive instruction in its theoretical and applied so that any scientist with even modest molecular biology experience can effectively employ it. The manual reflects nearly a decade of experience with students of greatly varying technical expertise andexperience who attended a course on the technology at Cold Spring Harbor Laboratory. Phage-display technology is growing in importance and power. This manual is an unrivalled source of expertise in its execution and application.

Download or read book Targeted Radionuclide Therapy written by Tod W. Speer and published by Lippincott Williams & Wilkins. This book was released on 2010-11-15 with total page 564 pages. Available in PDF, EPUB and Kindle. Book excerpt: Offering an overview of radioimmunotherapy, this book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy.

Download or read book Engineering in Translational Medicine written by Weibo Cai and published by Springer Science & Business Media. This book was released on 2013-12-19 with total page 997 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book covers a broad area of engineering research in translational medicine. Leaders in academic institutions around the world contributed focused chapters on a broad array of topics such as: cell and tissue engineering (6 chapters), genetic and protein engineering (10 chapters), nanoengineering (10 chapters), biomedical instrumentation (4 chapters), and theranostics and other novel approaches (4 chapters). Each chapter is a stand-alone review that summarizes the state-of-the-art of the specific research area. Engineering in Translational Medicine gives readers a comprehensive and in-depth overview of a broad array of related research areas, making this an excellent reference book for scientists and students both new to engineering/translational medicine and currently working in this area. The ability for engineering approaches to change biomedical research are increasing and having significant impact. Development of basic assays and their numerous applications are allowing for many new discoveries and should eventually impact human health. This book brings together many diverse yet related topics to give the reader a solid overview of many important areas that are not found together elsewhere. Dr. Weibo Cai has taken great care to select key research leaders of many sub-disciplines who have put together very detailed chapters that are easy to read yet highly rich in content. _______________ This book brings together many diverse yet related topics to give the reader a solid overview of many important areas that are not found together elsewhere. Dr. Weibo Cai has taken great care to select key research leaders of many sub-disciplines who have put together very detailed chapters that are easy to read yet highly rich in content. It is very exciting to see such a great set of chapters all together to allow one to have a key understanding of many different areas including cell, gene, protein, and nano engineering as well as the emerging field of theranostics. I am sure the readers will find this collection of important chapters helpful in their own research and understanding of how engineering has and will continue to play a critical role in biomedical research and clinical translation. Sanjiv Sam Gambhir M.D., Ph.D. Stanford University, USA Engineering in Translational Medicine is a landmark book bridging the fields of engineering and medicine with a focus on translational technologies and methods. In a single, well-coordinated volume, this book brings together contributions from a strong and international scientific cast, broadly covering the topics. The book captures the tremendous opportunities made possible by recent developments in bioengineering, and highlights the potential impact of these advances across a broad spectrum of pressing health care needs. The book can equally serve as a text for graduate level courses, a reference source, a book to be dipped into for pleasure by those working within the field, or a cover-to-cover read for those wanting a comprehensive, yet readable introduction to the current state of engineering advances and how they are impacting translational medicine. Simon R. Cherry, Ph.D. University of California, Davis, USA

Download or read book Antibody Fusion Proteins written by Steven M. Chamow and published by Wiley-Liss. This book was released on 1999-04-13 with total page 312 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thoroughly detailed and illustrated, this book examines the construction, properties, applications, and problems associated with specific types of fusion molecules used in clinical and research medicine. The editors present an overview of the field, followed by nine chapters divided into two general sections based on the two primary parts of the antibody molecule: Fab fusion proteins and Fc fusion proteins. In addition, numerous renowned scientists in the field have contributed outlines demonstrating man-made molecules that will be required not only to overcome the limitations of monoclonal antibodies, but also to extend the principle of selective targeting. Divided into specific, accessible sections, Antibody Fusion Proteins includes: * Chapters describing Fc fusion proteins, as well as several classes of antigen-binding proteins * Complete details on the design and molecular construction of genetically engineered fusion molecules * Useful information on molecular purification, large-scale production, practical applications, and their therapeutic potential * The latest data on forming fusion proteins with toxins, cytokines, or enzymes that can activate a prodrug

Download or read book Therapeutic Proteins written by Roland Kontermann and published by John Wiley & Sons. This book was released on 2012-03-26 with total page 373 pages. Available in PDF, EPUB and Kindle. Book excerpt: For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.

Download or read book Drug Diagnostics Co Development in Oncology written by Jan Trøst Jørgensen and published by Frontiers E-books. This book was released on 2014-11-07 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt: The idea of combining drugs and diagnostics in oncology is not new. When the selective estrogen receptor modulator tamoxifen was developed in the 1970’s for the treatment of breast cancer a positive correlation between receptor status and treatment outcome was found. As a result of this research, it was suggested to use the estrogen-receptor assay as a diagnostic test for selection of patients for tamoxifen treatment. Despite this suggestion was put forward nearly 40 years ago the adaptation of the drug-diagnostic co-development model has been relatively slow and it is only within the last decade that it has gained more widespread acceptance. The parallel development of the monoclonal antibody trastuzumab (Herceptin®, Roche/Genentech) and the immunohistochemistry assay for HER2 protein overexpression (HercepTest™, Dako) seems to have served as an inspiration to a number of stakeholders such as pharma and diagnostic companies, regulatory agencies, and academia. In recent years we have seen an increasing number of oncology drug development projects that have taken advantage of the drug-diagnostic co-development model, as outline below. Most of the new targeted anti-cancer drugs that have been introduced in recent years, such as BRAF-, ALK-, EGFR- and HER2-inhibitors, are more or less all a product of the drugdiagnostic co-development model. These drugs have shown remarkable high response rates in selected groups of patients within cancer diseases with great unmet medical needs. This Research Topic on Drug-Diagnostic Co-Development in Oncology aims to provide you with an insight into some of the diverse activities that constitute this new research area.

Download or read book Beyond the Molecular Frontier written by National Research Council and published by National Academies Press. This book was released on 2003-03-19 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: Chemistry and chemical engineering have changed significantly in the last decade. They have broadened their scopeâ€"into biology, nanotechnology, materials science, computation, and advanced methods of process systems engineering and controlâ€"so much that the programs in most chemistry and chemical engineering departments now barely resemble the classical notion of chemistry. Beyond the Molecular Frontier brings together research, discovery, and invention across the entire spectrum of the chemical sciencesâ€"from fundamental, molecular-level chemistry to large-scale chemical processing technology. This reflects the way the field has evolved, the synergy at universities between research and education in chemistry and chemical engineering, and the way chemists and chemical engineers work together in industry. The astonishing developments in science and engineering during the 20th century have made it possible to dream of new goals that might previously have been considered unthinkable. This book identifies the key opportunities and challenges for the chemical sciences, from basic research to societal needs and from terrorism defense to environmental protection, and it looks at the ways in which chemists and chemical engineers can work together to contribute to an improved future.

Download or read book Protein Engineering Techniques written by Krishna Mohan Poluri and published by Springer. This book was released on 2016-11-12 with total page 144 pages. Available in PDF, EPUB and Kindle. Book excerpt: This brief provides a broad overview of protein-engineering research, offering a glimpse of the most common experimental methods. It also presents various computational programs with applications that are widely used in directed evolution, computational and de novo protein design. Further, it sheds light on the advantages and pitfalls of existing methodologies and future perspectives of protein engineering techniques.

Download or read book Molecular Biology of the Cell written by and published by . This book was released on 2002 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Peptide Antibodies written by Gunnar Houen and published by Humana. This book was released on 2015-10-02 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This extensive volume covers basic and advanced aspects of peptide antibody production, characterization and uses. Although peptide antibodies have been available for many years, they continue to be a field of active research and method development. For example, peptide antibodies which are dependent on specific posttranslational modifications are of great interest, such as phosphorylation, citrullination and others, while different forms of recombinant peptide antibodies are gaining interest, notably nanobodies, single chain antibodies, TCR-like antibodies, among others. Within this volume, those areas are covered, as well as several technical and scientific advances: solid phase peptide synthesis, peptide carrier conjugation and immunization, genomics, transcriptomics, proteomics and elucidation of the molecular basis of antigen presentation and recognition by dendritic cells, macrophages, B cells and T cells. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Peptide Antibodies: Methods and Protocols serves as an ideal reference for researchers exploring this vital and expansive area of study.

Download or read book Protein Therapeutics 2 Volume Set written by Tristan Vaughan and published by John Wiley & Sons. This book was released on 2017-12-04 with total page 762 pages. Available in PDF, EPUB and Kindle. Book excerpt: Branchenführende Big-Pharma-Unternehmen und erstklassige Forscher präsentieren grundlegende Konzepte und Herausforderungen bei proteinbasierten Pharmazeutika. Beinhaltet auch eine Einführung in die aus Sicht der Arzneimittelentwicklung fünf wesentlichen Anwendungsbereiche.

Download or read book Heat Shock Proteins in Cancer written by Stuart K. Calderwood and published by Springer Science & Business Media. This book was released on 2007-09-09 with total page 399 pages. Available in PDF, EPUB and Kindle. Book excerpt: Heat shock proteins are emerging as important molecules in the development of cancer and as key targets in cancer therapy. These proteins enhance the growth of cancer cells and protect tumors from treatments such as drugs or surgery. However, new drugs have recently been developed particularly those targeting heat shock protein 90. As heat shock protein 90 functions to stabilize many of the oncogenes and growth promoting proteins in cancer cells, such drugs have broad specificity in many types of cancer cell and offer the possibility of evading the development of resistance through point mutation or use of compensatory pathways. Heat shock proteins have a further property that makes them tempting targets in cancer immunotherapy. These proteins have the ability to induce an inflammatory response when released in tumors and to carry tumor antigens to antigen presenting cells. They have thus become important components of anticancer vaccines. Overall, heat shock proteins are important new targets in molecular cancer therapy and can be approached in a number of contrasting approaches to therapy.

Download or read book Handbook of Therapeutic Antibodies written by Stefan Dübel and published by John Wiley & Sons. This book was released on 2014-12-03 with total page 2538 pages. Available in PDF, EPUB and Kindle. Book excerpt: Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.

Download or read book Innovations for Next Generation Antibody Drug Conjugates written by Marc Damelin and published by Springer. This book was released on 2018-05-29 with total page 358 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.